Further studies are necessary to understand how inhibiting or activating the VIP–VPAC axis may serve as a prognostic biomarker of cancer metastasis or a predictive biomarker for response to VIP-targeted therapies on EMT in gastrointestinal malignancies. This evidence concerns the gene VIP and cancer.